LEXINGTON, Mass., Sept. 26, 2018 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the developmentand commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that the Company will present at the Cantor Fitzgerald 2018 Global Healthcare Conference on Tuesday, October 2 at
James Dentzer, the Company's new President & Chief Executive Officer, will provide a brief overview of the Company's pipeline of drug candidates and business strategy.
A live webcast of the presentation will be available by visiting the investor section of Curis' website http://investors.curis.com/events-and-presentations.
A replay of the webcast will be archived on the website for 30 days following the presentation.
About CurisCuris is a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, including fimepinostat, which is being investigated in clinical studies in patients with DLBCL and solid tumors. Curis is also engaged in a collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including, the PDL1/VISTA antagonist CA-170, and the PDL1/TIM3 antagonist CA-327, as well as the IRAK4 kinase inhibitor, CA-4948. CA-170 is currently undergoing testing in a Phase 1 trial in patients with advanced solid tumors and lymphomas, and in a Phase 2 trial in India conducted by Aurigene. CA-4948 is currently undergoing testing in a Phase 1 trial in patients with non-Hodgkin lymphoma. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis's website at www.curis.com.
View original content:http://www.prnewswire.com/news-releases/curis-to-present-at-the-cantor-fitzgerald-global-healthcare-conference-300719582.html
SOURCE Curis, Inc.
Subscribe to our Free Newsletters!